2/11/2019 8:05:39 AM
Seattle Genetics Achieves $30 Mln Milestone Payment For EC Approval Of ADCETRIS
2/7/2019 4:37:48 PM
Seattle Genetics Q4 Loss/share $0.75 Vs. Loss $0.41 Year Ago
1/9/2019 8:09:19 AM
Seattle Publishes North American Subgroup Data From ECHELON-1 Phase 3 Trial Of ADCETRIS In Newly Diagnosed Advanced HL
12/3/2018 9:31:26 PM
Seattle Genetics And Takeda Present Positive Data From Phase 3 ECHELON-2 Trial For ADCETRIS
12/1/2018 12:30:24 PM
Seattle Genetics Highlights Multiple Data Sets Evaluating Combination Of ADCETRIS And Opdivo At ASH Annual Meeting
11/16/2018 12:11:54 PM
Seattle Genetics Announces FDA Approval Of ADCETRIS In Combination With Chemotherapy For Adults
11/15/2018 8:04:24 AM
Seattle Genetics: FDA Grants Breakthrough Therapy Designation To ADCETRIS For Frontline Peripheral T-Cell Lymphomas
11/14/2018 8:02:26 AM
Seattle Genetics Begins Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma
11/5/2018 8:02:31 AM
Seattle Genetics Submits SBLA For ADCETRIS In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas
10/26/2018 8:02:35 AM
Seattle Genetics Announces Multiple Data Presentations Of ADCETRIS In Patients With Hodgkin Lymphoma At ISHL 2018
10/25/2018 4:30:56 PM
Seattle Genetics Q3 Loss/share $0.42 Vs. Profit $0.34 Year Ago
10/1/2018 6:47:57 AM
Seattle Genetics, Takeda Report Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS
9/21/2018 10:52:12 AM
Seattle Genetics Announces ADCETRIS Approval In Japan For Frontline Hodgkin Lymphoma
9/18/2018 4:07:42 PM
BioClin Therapeutics Appoints Scott Myers As CEO